Amgen regains rights to Prolia/Xgeva, Vectibix

Amgen Inc. (NASDAQ:AMGN) regained all remaining rights from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to Prolia denosumab, Xgeva denosumab and Vectibix panitumumab in 48 territories, including Brazil; China, including Hong Kong; Colombia; India; Israel; Singapore; South Korea; Taiwan; and Thailand.

Amgen spokesperson Kristen Davis said Amgen initially partnered with GSK to "capitalize on GSK's established presence in these markets," but the biotech is now attempting to grow internationally itself. ...